IMVT
HealthcareImmunovant, Inc.
$24.97
$-0.94 (-3.63%)
Jan 5, 2026
Price History (1Y)
Analysis
Immunovant, Inc. is a biotechnology company listed in the healthcare sector. The company has a market capitalization of $5.03 billion and employs 362 individuals. The financial health of Immunovant, Inc. indicates significant losses. The company reported net income and EBITDA of -$464,686,016 and -$486,694,016 respectively for the trailing twelve months (TTM). Free cash flow was also negative at -$269,797,248. However, the company has a substantial amount of cash on hand, totaling $521.87 million. The valuation context of Immunovant, Inc. is characterized by significant losses and a low forward price-to-earnings ratio of -8.33. The company's price-to-book ratio is 8.38, suggesting that its stock price may be higher than its book value. However, the negative earnings growth rates are not reflected in the provided data.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Visit website →Key Statistics
- Market Cap
- $5.03B
- P/E Ratio
- N/A
- 52-Week High
- $27.69
- 52-Week Low
- $12.72
- Avg Volume
- 1.79M
- Beta
- 0.57
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 362